Chroma licenses CTI to co-develop, market Tosedostat
Under the pact, CTI is expected to initiate a Phase III trial in US and Europe in elderly patients with relapsed or refractory acute myeloid leukemia (AML) for
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.